Dawn Owen1,2, Fawaad Iqbal3, Bruce E Pollock1,4, Michael J Link4, Kathy Stien2, Yolanda I Garces1, Paul D Brown5, Robert L Foote1. 1. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. 2. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 3. RS McLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada. 4. Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota. 5. Department of Radiation Oncology, MD Anderson Cancer Centre, Houston, Texas.
Abstract
BACKGROUND: Stereotactic radiosurgery is widely applied to deliver additional dose to head and neck tumors. However, its safety and efficacy remains equivocal. METHODS: One hundred eighty-four patients with primary head and neck cancers treated between January 1990 and August 2012 with Gamma Knife stereotactic radiosurgery were retrospectively reviewed. RESULTS: Two hundred fifteen sites were treated with Gamma Knife stereotactic radiosurgery among 184 patients. Fifty-one percent of patients received concurrent external beam radiotherapy (EBRT), 72% had prior surgery, and 46% received chemotherapy. Most (44%) had squamous cell carcinoma and most patients (65%) were treated for recurrent disease. With a median follow-up of 17.3 months, 12-month local control was 82%. Late effects occurred in 59 patients with the most common being temporal lobe necrosis (15 patients). CONCLUSION: Radiosurgery can provide tumor control for patients with head and neck cancers involving the skull base. Long-term follow-up is important in survivors to identify late effects.
BACKGROUND: Stereotactic radiosurgery is widely applied to deliver additional dose to head and neck tumors. However, its safety and efficacy remains equivocal. METHODS: One hundred eighty-four patients with primary head and neck cancers treated between January 1990 and August 2012 with Gamma Knife stereotactic radiosurgery were retrospectively reviewed. RESULTS: Two hundred fifteen sites were treated with Gamma Knife stereotactic radiosurgery among 184 patients. Fifty-one percent of patients received concurrent external beam radiotherapy (EBRT), 72% had prior surgery, and 46% received chemotherapy. Most (44%) had squamous cell carcinoma and most patients (65%) were treated for recurrent disease. With a median follow-up of 17.3 months, 12-month local control was 82%. Late effects occurred in 59 patients with the most common being temporal lobe necrosis (15 patients). CONCLUSION: Radiosurgery can provide tumor control for patients with head and neck cancers involving the skull base. Long-term follow-up is important in survivors to identify late effects.
Authors: Nauman H Malik; Michael S Kim; Hanbo Chen; Ian Poon; Zain Husain; Antoine Eskander; Gabriel Boldt; Alexander V Louie; Irene Karam Journal: Adv Radiat Oncol Date: 2020-11-28
Authors: Alexandria Harris; Jinhong Li; Karley Atchison; Christine Harrison; Daniel Hall; Tyler VanderWeele; Jonas T Johnson; Marci L Nilsen Journal: Cancer Med Date: 2022-03-11 Impact factor: 4.711